Darolutamide

Manufactured by MedChemExpress

Darolutamide is a lab equipment product manufactured by MedChemExpress. It is a small molecule that functions as an androgen receptor antagonist.

Automatically generated - may contain errors

Lab products found in correlation

Apalutamide, by MedChemExpress (2 mentions) R1881, by PerkinElmer (1 mentions) Incucyte zoom, by Sartorius (1 mentions) Olaparib, by MedChemExpress (1 mentions) Paclitaxel, by MedChemExpress (1 mentions) Enzalutamide, by MedChemExpress (1 mentions) Mibolerone, by PerkinElmer (1 mentions)

Spelling variants of this product

Darolutamide (Daro (2 citations)

2 protocols using darolutamide

Live Cell Proliferation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols

The proliferation measurements were performed as described before^{44 (link)} by live cell analysis (IncuCyte ZOOM, Essen BioScience) using a nuclear mKate2 fluorescent label.
For proliferation experiments we used apalutamide (HY-16060), darolutamide (HY-16985), paclitaxel (HY-B0015), olaparib (HY-10162), and obatoclax (HY-10969) from MedChemExpress as well as enzalutamide (Sequoia Research Products, SRP016825m; and MedChemExpress, HY-70002), RD-162 (Sequoia Research Products), abiraterone acetate (Sequoia Research Products, SRP00371a), R1881 (Perkin Elmer, NLP005), and docetaxel (Fluka, 01885).

Handle F., Prekovic S., Helsen C., Van den Broeck T., Smeets E., Moris L., Eerlings R., Kharraz S.E., Urbanucci A., Mills I.G., Joniau S., Attard G, & Claessens F. (2019). Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports, 9, 13786.

+ Open protocol

+ Expand

Comparative Analysis of Androgen Receptor Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

CT7001 was provided by Carrick Therapeutics. Apalutamide, enzalutamide, darolutamide and bavdegalutamide were purchased from MedChemExpress. Mibolerone was purchased from PerkinElmer.

Constantin T.A., Varela-Carver A., Greenland K.K., de Almeida G.S., Olden E., Penfold L., Ang S., Ormrod A., Leach D.A., Lai C.F., Ainscow E.K., Bahl A.K., Carling D., Fuchter M.J., Ali S, & Bevan C.L. (2023). The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. British Journal of Cancer, 128(12), 2326-2337.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!